NOVABAY PHARMACEUTICALS INC (NBY) Fundamental Analysis & Valuation

NYSEARCA:NBY • US66987P4090

1.26 USD
+0.02 (+1.61%)
At close: Mar 10, 2026
1.19 USD
-0.07 (-5.56%)
Pre-Market: 3/11/2026, 5:29:10 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This NBY fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

NBY gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. NBY has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, NBY is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. NBY Profitability Analysis

1.1 Basic Checks

  • NBY had negative earnings in the past year.
  • In the past year NBY has reported a negative cash flow from operations.
  • NBY had negative earnings in each of the past 5 years.
  • NBY had a negative operating cash flow in each of the past 5 years.
NBY Yearly Net Income VS EBIT VS OCF VS FCFNBY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

  • The Return On Assets of NBY (-251.48%) is worse than 88.60% of its industry peers.
Industry RankSector Rank
ROA -251.48%
ROE N/A
ROIC N/A
ROA(3y)-178.5%
ROA(5y)-127.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NBY Yearly ROA, ROE, ROICNBY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K 4K 6K

1.3 Margins

  • With a decent Gross Margin value of 66.26%, NBY is doing good in the industry, outperforming 75.13% of the companies in the same industry.
  • NBY's Gross Margin has declined in the last couple of years.
  • NBY does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 66.26%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.12%
GM growth 5Y-2.09%
NBY Yearly Profit, Operating, Gross MarginsNBY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. NBY Health Analysis

2.1 Basic Checks

  • NBY does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, NBY has more shares outstanding
  • Compared to 5 years ago, NBY has more shares outstanding
  • NBY has a worse debt/assets ratio than last year.
NBY Yearly Shares OutstandingNBY Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
NBY Yearly Total Debt VS Total AssetsNBY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

  • Based on the Altman-Z score of -71.73, we must say that NBY is in the distress zone and has some risk of bankruptcy.
  • NBY's Altman-Z score of -71.73 is on the low side compared to the rest of the industry. NBY is outperformed by 92.23% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -71.73
ROIC/WACCN/A
WACC9.56%
NBY Yearly LT Debt VS Equity VS FCFNBY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

  • A Current Ratio of 0.68 indicates that NBY may have some problems paying its short term obligations.
  • The Current ratio of NBY (0.68) is worse than 89.12% of its industry peers.
  • NBY has a Quick Ratio of 0.68. This is a bad value and indicates that NBY is not financially healthy enough and could expect problems in meeting its short term obligations.
  • NBY's Quick ratio of 0.41 is on the low side compared to the rest of the industry. NBY is outperformed by 89.12% of its industry peers.
Industry RankSector Rank
Current Ratio 0.68
Quick Ratio 0.41
NBY Yearly Current Assets VS Current LiabilitesNBY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. NBY Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 84.82% over the past year.
  • NBY shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -33.58%.
  • The Revenue has been growing by 8.19% on average over the past years. This is quite good.
EPS 1Y (TTM)84.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.24%
Revenue 1Y (TTM)-33.58%
Revenue growth 3Y5.12%
Revenue growth 5Y8.19%
Sales Q2Q%-38.05%

3.2 Future

  • Based on estimates for the next years, NBY will show a very strong growth in Earnings Per Share. The EPS will grow by 31.55% on average per year.
  • NBY is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.46% yearly.
EPS Next Y39.01%
EPS Next 2Y31.55%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year11.73%
Revenue Next 2Y21.46%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NBY Yearly Revenue VS EstimatesNBY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M
NBY Yearly EPS VS EstimatesNBY Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -2K -4K -6K -8K

More info and screens

Find the best growth stocksShow best growing peers

1

4. NBY Valuation Analysis

4.1 Price/Earnings Ratio

  • NBY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NBY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NBY Price Earnings VS Forward Price EarningsNBY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NBY Per share dataNBY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as NBY's earnings are expected to grow with 31.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.55%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. NBY Dividend Analysis

5.1 Amount

  • NBY has a Yearly Dividend Yield of 57.55%, which is a nice return.
  • The stock price of NBY dropped by -91.00% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
  • NBY's Dividend Yield is rather good when compared to the industry average which is at 0.70. NBY pays more dividend than 100.00% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.82, NBY pays a better dividend.
Industry RankSector Rank
Dividend Yield 57.55%

5.2 History

  • NBY is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
NBY Yearly Dividends per shareNBY Yearly Dividends per shareYearly Dividends per share 2025 0 0 0 0 0

5.3 Sustainability

DPN/A
EPS Next 2Y31.55%
EPS Next 3YN/A
NBY Yearly Income VS Free CF VS DividendNBY Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

More info and screens

Find the best dividend stocksShow peers with best dividend

NBY Fundamentals: All Metrics, Ratios and Statistics

NOVABAY PHARMACEUTICALS INC

NYSEARCA:NBY (3/10/2026, 8:04:00 PM)

Premarket: 1.19 -0.07 (-5.56%)

1.26

+0.02 (+1.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05
Earnings (Next)03-31
Inst Owners5.45%
Inst Owner Change1891.11%
Ins Owners4.89%
Ins Owner Change0%
Market Cap32.91M
Revenue(TTM)9.78M
Net Income(TTM)-8.61M
Analysts80
Price TargetN/A
Short Float %N/A
Short Ratio1.57
Dividend
Industry RankSector Rank
Dividend Yield 57.55%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-17.67%
Min Revenue beat(2)-27.48%
Max Revenue beat(2)-7.85%
Revenue beat(4)0
Avg Revenue beat(4)-20.15%
Min Revenue beat(4)-27.48%
Max Revenue beat(4)-7.85%
Revenue beat(8)2
Avg Revenue beat(8)-7.51%
Revenue beat(12)4
Avg Revenue beat(12)-7.15%
Revenue beat(16)5
Avg Revenue beat(16)-5.76%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.36
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-7.41
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS0.37
BVpS0
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -251.48%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 66.26%
FCFM N/A
ROA(3y)-178.5%
ROA(5y)-127.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.12%
GM growth 5Y-2.09%
F-Score4
Asset Turnover2.86
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15%
Cap/Sales 0.06%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.68
Quick Ratio 0.41
Altman-Z -71.73
F-Score4
WACC9.56%
ROIC/WACCN/A
Cap/Depr(3y)15.76%
Cap/Depr(5y)29.79%
Cap/Sales(3y)0.32%
Cap/Sales(5y)0.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)84.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.24%
EPS Next Y39.01%
EPS Next 2Y31.55%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-33.58%
Revenue growth 3Y5.12%
Revenue growth 5Y8.19%
Sales Q2Q%-38.05%
Revenue Next Year11.73%
Revenue Next 2Y21.46%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y0.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year51.27%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-34.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-34.57%
OCF growth 3YN/A
OCF growth 5YN/A

NOVABAY PHARMACEUTICALS INC / NBY FAQ

Can you provide the ChartMill fundamental rating for NOVABAY PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 2 / 10 to NBY.


Can you provide the valuation status for NOVABAY PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 1 / 10 to NOVABAY PHARMACEUTICALS INC (NBY). This can be considered as Overvalued.


Can you provide the profitability details for NOVABAY PHARMACEUTICALS INC?

NOVABAY PHARMACEUTICALS INC (NBY) has a profitability rating of 1 / 10.


What is the expected EPS growth for NOVABAY PHARMACEUTICALS INC (NBY) stock?

The Earnings per Share (EPS) of NOVABAY PHARMACEUTICALS INC (NBY) is expected to grow by 39.01% in the next year.